Retrospective comparison of single-agent chemotherapy with weekly 5-fluorouracil or weekly irinotecan in previously treated patients with metastatic colorectal cancer

Journal of Chemotherapy

Volumn 14, Issue 1, 2002, Pages 84-87

  Lavrenkov, Konstantin ^a   Man, S ^a   Mermershtain, W ^a   Cohen, Y ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

High dose 5 fluorouracil; Irinotecan; Metastatic colorectal cancer; Retrospective analysis; Second line chemotherapy

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; COLORECTAL CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; DIARRHEA; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MONOTHERAPY; NEUTROPENIA; RECURRENT CANCER; RETROSPECTIVE STUDY;

EID: 0036199461     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2002.14.1.84     Document Type: Article

References (17)

1. The chemotherapy of colon cancer can no longer be ignored
2. Colorectal cancer chemotherapy: Irinotecan
3. Modulation of 5-fluorouracil with leucovorin in patients with advanced colorectal cancer: A meta-analysis
4. CPT-11 in gastrointestinal cancer
5. Phase II study of weekly high dose fluorouracil in previously treated patients with metastatic colorectal cancer
6. Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metatstatic colorectal cancer
7. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer
8. Topoisomerase I inhibitors: Review and update
9. Patient preferences for oral versus intravenous palliative chemotherapy
10. Oxaliplatin monotherapy: Phase II trials in advanced colorectal cancer
11. Irinotecan in advanced colorectal cancer patients with progression after therapy with 5-FU
12. Weekly irinotecan as a single agent, in heavily pretreated patients with advanced colorectal cancer and low performance status
13. Phase II, prospective, open-label study of a weekly schedule of irinotecan with advanced colorectal cancer
14. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer
15. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy naive patients and patients pretreated with fluorouracil-based chemotherapy
16. Phase II trial of irinotecan in patients with metastatic colorectal cancer
17. Regional and systemic therapies for advanced colorectal carcinoma: Randomized clinical trial results